Company intelligence / Profile preview

Cannasoul Lab Services

Ne'urim, Center District, Israel

Ownership: Private
Development stage: Other

Overview

No clinical trial results published; pipeline assets are in discovery/preclinical validation, with drug profiling and biomarker analytics as main outputs

Therapeutic areas: OncologyNeurologyEndocrinology
Modalities: Small molecule (cannabinoids, psilocybin analogs)
Industry: Biotech

Partnerships

Synaptogenix (25% stake partnership for joint R&D/pharma development)Technion – Israel Institute of Technology (founding/co-development partner)

Beyond the preview

Go deeper on Cannasoul Lab Services.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cannasoul Lab Services.

Explore the full profile